Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Dividend Shares

Will the Diageo share price crash again in 2026?

The Diageo share price has crashed 35.6% over one year, making it one of the FTSE 100's worst performers in…

Read more »

Investing Articles

Is Alphabet still one of the best shares to buy heading into 2026?

The best time to buy shares is when other investors are seeing risks. Is that the case with Google’s parent…

Read more »

Investing Articles

Could the Barclays share price be the FTSE 100’s big winner in 2026?

With OpenAI and SpaceX considering listing on the stock market, could investment banking revenues push the Barclays share price higher…

Read more »

Investing Articles

Will the Nvidia share price crash in 2026? Here are the risks investors can’t ignore

Is Nvidia’s share price in danger in 2026? Stephen Wright outlines the risks – and why some might not be…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Growth Shares

I asked ChatGPT how much £10,000 invested in Lloyds shares 5 years ago is worth today? But it wasn’t very helpful…

Although often impressive, artificial intelligence has its flaws. James Beard found this out when he used it to try and…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Did ChatGPT give me the best FTSE stocks to buy 1 year ago?

ChatGPT can do lots of great stuff, but is it actually any good at identifying winning stocks from the FTSE…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Who will be next year’s FTSE 100 Christmas cracker?

As we approach Christmas 2025, our writer identifies the FTSE 100’s star performer this year. But who will be number…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

I asked ChatGPT for an 8%-yielding passive income portfolio of dividend shares and it said…

Mark Hartley tested artificial intelligence to see if it understood how to build an income portfolio from dividend shares. He…

Read more »